1. A Retrospective Analysis of Clinical Outcomes of Patients Older Than or Equal to 80 Years with Small Cell Lung Cancer 
Toshiyuki Noguchi, MD, Hideaki Mochizuki, MD, Mariko Yamazaki, MD, Eriko Kawate, MD, Yohei Suzuki, MD, Teruhiko Sato, MD, PhD, Hideki Takahashi, MD, PhD 
Journal of Thoracic Oncology 
Volume 5, Issue 7, Pages (July 2010)
DOI: /JTO.0b013e3181de7173
Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Comparison of survival curves according to the two independent factors: age (70–79 years versus 80+ years) and treatment for primary tumor. The solid thin line represents the group aged 70 to 79 years with treatment (TX+) (n = 33, MST: 11.1 months), the solid bold line that of patients aged 80+ years with treatment (n = 24, MST: 13.1 months), the broken thin line that of patients aged 70 to 79 years without treatment (TX−) (n = 5, MST: 2.1 months), and the broken bold line that of patients aged 80+ years without treatment (n = 21, MST: 2.5 months). Survival was significantly longer in treated groups than untreated groups regardless of age (p < 0.01). MST, median survival time.
Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181de7173)
Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Comparison of survival curves of the treated (TX+) and untreated (TX−) patients aged 80+ years according to PS (PS 0–1 versus PS 2–3). The solid thin line represents the survival curve of the treated patients with PS 0 to 1 (n = 17, MST: 20.4 months), the solid bold line that of treated patients with PS 2 to 3 (n = 7, MST: 9.1 months), the broken thin line that of untreated patients with PS 0 to 1 (n = 4, MST: 6.9 months), and the broken bold line that of untreated patients with PS 2 to 3 (n = 13, MST: 1.9 months). Longer survival was observed in patients with better PS in the treated patients (p < 0.01). MST, median survival time; PS, performance status.
Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181de7173)
Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Comparison of survival curves of the treated (TX+) and untreated (TX−) patients aged 80+ years according to Charlson index (CI) (CI 0–1 versus CI 2–3). The solid thin line represents the survival curve of the treated (TX+) patients with CI 0 or 1 (n = 14, MST: 13.0 months), the solid bold line that of the treated patients with CI 2 to 3 (n = 10, MST: 11.1 months), the broken thin line that of untreated (TX−) patients with CI 0 to 1 (n = 9, MST: 2.9 months), and the broken bold line that of untreated patients with CI 2 to 3 (n = 10, MST: 2.5 months). The treated patients with CI 2 to 3 survived significantly longer than those left untreated (p < 0.01). MST, median survival time.
Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181de7173)
Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions